title: Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
abstract: BACKGROUND
  In colon cancer patients, obesity, sedentary lifestyle, and high dietary glycemic load have been associated with increased risk of cancer recurrence. High sugar-sweetened beverage intake has been associated with obesity, diabetes, and cardio-metabolic diseases, but the influence on colon cancer survival is unknown.
  
  
  METHODS
  We assessed the association between sugar-sweetened beverage consumption on cancer recurrence and mortality in 1,011 stage III colon cancer patients who completed food frequency questionnaires as part of a U.S. National Cancer Institute-sponsored adjuvant chemotherapy trial. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated with Cox proportional hazard models.
  
  
  RESULTS
  Patients consuming ≥ 2 servings of sugar-sweetened beverages per day experienced an adjusted HR for disease recurrence or mortality of 1.67 (95% CI, 1.04-2.68), compared with those consuming <2 servings per month (P(trend) = 0.02). The association of sugar-sweetened beverages on cancer recurrence or mortality appeared greater among patients who were both overweight (body mass index ≥ 2 5 kg/m(2)) and less physically active (metabolic equivalent task-hours per week <18) (HR = 2.22; 95% CI, 1.29-3.81, P(trend) = 0.0025).
  
  
  CONCLUSIONS
  Higher sugar-sweetened beverage intake was associated with a significantly increased risk of cancer recurrence and mortality in stage III colon cancer patients.
authors.affiliation: Brown University, Providence, Rhode Island, United States of America.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Fuchs
authors.affiliation: Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
authors.forename: Kaori
authors.initials: K
authors.lastname: Sato
authors.affiliation: Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina, United States of America.
authors.forename: Donna
authors.initials: D
authors.lastname: Niedzwiecki
authors.affiliation: Alliance Statistics and Data Center, Duke University Medical Center, Durham, North Carolina, United States of America.
authors.forename: Xing
authors.initials: X
authors.lastname: Ye
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
authors.forename: Leonard B
authors.initials: LB
authors.lastname: Saltz
authors.affiliation: Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mayer
authors.affiliation: Toledo Community Hospital Oncology Program, Toledo, Ohio, United States of America.
authors.forename: Rex B
authors.initials: RB
authors.lastname: Mowat
authors.affiliation: Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada.
authors.forename: Renaud
authors.initials: R
authors.lastname: Whittom
authors.affiliation: Loyola University Stritch School of Medicine, Naperville, Illinois, United States of America.
authors.forename: Alexander
authors.initials: A
authors.lastname: Hantel
authors.affiliation: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States of America.
authors.forename: Al
authors.initials: A
authors.lastname: Benson
authors.affiliation: Virginia Oncology Associates, Norfolk, Virginia, United States of America.
authors.forename: Daniel
authors.initials: D
authors.lastname: Atienza
authors.affiliation: Southeast Cancer Control Consortium, Mission Hospitals, Inc., Asheville, North Carolina, United States of America.
authors.forename: Michael
authors.initials: M
authors.lastname: Messino
authors.affiliation: University of Chicago, Chicago, Illinois, United States of America.
authors.forename: Hedy
authors.initials: H
authors.lastname: Kindler
authors.affiliation: University of California at San Francisco Comprehensive Cancer Center, San Francisco, California, United States of America.
authors.forename: Alan
authors.initials: A
authors.lastname: Venook
authors.affiliation: Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
authors.forename: Shuji
authors.initials: S
authors.lastname: Ogino
authors.affiliation: Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States of America.
authors.forename: Kana
authors.initials: K
authors.lastname: Wu
authors.affiliation: Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States of America; Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America.
authors.forename: Walter C
authors.initials: WC
authors.lastname: Willett
authors.affiliation: Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, United States of America.
authors.forename: Edward L
authors.initials: EL
authors.lastname: Giovannucci
authors.affiliation: Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Meyerhardt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001628:Beverages; D003110:Colonic Neoplasms / Q000401:mortality* / Q000473:pathology; D019422:Dietary Sucrose / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology / Q000401:mortality*; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012307:Risk Factors; D013549:Sweetening Agents / Q000009:adverse effects*; D055815:Young Adult
chemical_list: D019422:Dietary Sucrose; D013549:Sweetening Agents